Acromegaly and papillary thyroid carcinoma: A case series
Maryam Heidarpour, Hassan Rezvanian, Ali Kachuei
Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
|Date of Submission||14-Dec-2018|
|Date of Decision||22-May-2019|
|Date of Acceptance||26-Jun-2019|
|Date of Web Publication||30-Sep-2019|
Prof. Hassan Rezvanian
Isfahan Endocrine and Metabolism Research Center, Sedigheh Tahereh Research Complex, Khorram Street, Isfahan
Source of Support: None, Conflict of Interest: None
Acromegaly is a rare chronic disease and associated with an increased risk of malignancy. The issue of the risk of thyroid cancer in these patients is a topic of debate, and the number of large case–control studies is very limited. Several studies indicated that a chronic excess insulin-like growth factor-1 stimulates the proliferation of various cell types and induces an antiapoptotic effect in thyroid follicular cells. In the literature, the risk of thyroid cancer was reported greater than five-fold. In this review, we will briefly summarize the studies available regarding thyroid cancer in patients with acromegaly and present three case reports.
Keywords: Acromegaly, malignancy, thyroid cancer
|How to cite this article:|
Heidarpour M, Rezvanian H, Kachuei A. Acromegaly and papillary thyroid carcinoma: A case series. J Res Med Sci 2019;24:81
| Introduction|| |
Acromegaly is a rare chronic disease, characterized by excessive production of growth hormone (GH) and insulin-like growth factor-1 (IGF-1). Acromegaly is associated with increased morbidity and mortality. Cardiovascular complications have historically been reported contributing to half of the deaths. However, Ritvonen et al. according to a 20-year follow-up study reported that cardiovascular disease and malignancy accounted for 23% and 35% of deaths during the second decade, respectively. The relationship between GH/IGF-1 and tumor growth has been reported, and thyroid cancer was one of the most common cancer types in patients with acromegaly. The issue of the risk of thyroid cancer in these patients is a topic of debate, and the number of large case–control studies is very limited. In the literature, the risk of thyroid cancer was reported greater than five-fold. In this review, we will briefly summarize the studies available regarding thyroid cancer in patients with acromegaly and present our new case reports [Table 1]. It should be noted that the patients gave their informed consent for participation in the research.
|Table 1: Characteristics of our patients with acromegaly and thyroid cancer|
Click here to view
| Case Reports|| |
A 42-year-old male was referred to the endocrinology clinic in 2012 due to a thyroid nodule. The patient also complained of weight gain. Thyroid ultrasonography showed a 24 mm × 30 mm nodule in the middle of the left lobe with a hypoechoic pattern, irregular outline, and microcalcification. Fine-needle aspiration (FNA) was done, and papillary thyroid carcinoma (PTC) was reported. The physical appearance of the patient was suspected to be acromegaly. He had protruded chin, thickened lips, enlarged nose, deep voice, enlarged hand and feet, coarse skin, and excessive sweating. Laboratory values were notable for hemoglobin (Hb) A1c: 5.4% (4%–6.5%), fasting blood sugar (FBS): 94 mg/dl (77–99 mg/dl), IGF-1: 542 ng/dl (140–405 ng/dl), basal GH: 8.4 ng/ml (normal values were <1 ng/ml), oral glucose tolerance test (OGTT) (1 h after 75 mg oral glucose): 6.8 ng/ml, OGTT (2 h after 75 mg oral glucose): 5.7 ng/ml (normal value <1 ng/ml), thyroid-stimulating hormone (TSH): 1.2 mIU/ml (0.27-4.2 mIU/ml), free T4: 0.9 ng/dl (0.7-1.9 ng/dl), follicle-stimulating hormone (FSH); 9.1 mIU/ml (4.7–21.5 mIU/ml), luteinizing hormone (LH): 2.8 IU/L (0.5–16.9 IU/L), testosterone: 2.5 ng/ml (2–6.9 ng/ml), cortisol: 11 μg/dL at 8 am (10–20 μg/dL), and prolactin: 12 ng/ml (4–23 ng/ml). Brain magnetic resonance imaging (MRI) was performed and showed a macroadenoma in the pituitary gland. One month later, transsphenoidal surgery was done, and 8 months later, the patient underwent thyroidectomy and PTC was confirmed in the pathology report. On microscopic examination, there was no lymphovascular or capsular invasion. In the macroscopic evaluation of the lesion, the maximum mass diameter was 31 mm. Postoperatively, he received 100 mCi radioactive iodine and then he was put on 0.15 mg thyroxine once a day. Three months after thyroidectomy, laboratory values were notable for GH: 1.1 ng/ml, IGF-1: 460 ng/dl, OGTT (1 h): 0.6 ng/ml, OGTT (2 h): 0.7 ng/ml, and TSH: 0.1 mIU/ml. In late 2018, the patient's overall clinical condition was improved, and the laboratory test results showed prominent improvements, basal GH: 1 ng/ml, IGF-1: 257 ng/ml, thyroglobulin (on-levothyroxine): 0.7 ng/ml, and negative antithyroglobulin antibody. Now, the patient is feeling well.
A 28-year-old female was referred to the endocrinology clinic in 2017 due to a thyroid nodule. She also complained of size and weight gain gradually over the past 3 years. Thyroid ultrasound showed a 15 × mm 8 × mm × 18 mm hypoechoic nodule without calcification in the left thyroid lobe. FNA report was suspicious for PTC. Laboratory values were notable for FBS: 117 mg/dl, IGF-1: 1416 ng/dl (115–310 ng/dl), basal GH: 7.9 ng/ml (normal values were <1 ng/ml), OGTT (1 h): 6.4 ng/ml, OGTT (2 h): 6 ng/ml, TSH: 1 mIU/ml (0.27–4.2 mIU/ml), free T4: 1.9 ng/dl (0.7–1.9 ng/dl), prolactin: 12 ng/ml (4–23 ng/ml), cortisol: 17.5 μg/dL at 8 am (10–20 μg/dL), FSH: 9 mIU/ml (4.7–21.5 mIU/ml), LH: 8.1 IU/L (0.5–16.9 IU/L), and estradiol: 115 pg/ml. Brain MRI was performed and showed a macroadenoma in the pituitary gland. The patient underwent transsphenoidal surgery, and 4 months later, thyroidectomy was done. PTC was confirmed in pathology report, and there was lymphovascular and capsular invasion with two cervical lymph node metastases. Therefore, she received 100 mCi radioactive iodine. Three months later, laboratory values were notable for HbA1c: 5.8% (4%–6.5%), FBS: 90 mg/dl (77–99 mg/dl), IGF-1: 385 ng/dl (140–405 ng/dl), basal GH: 1 ng/ml (normal values were <1 ng/ml), OGTT (1 h after 75 mg oral glucose): 6.8 ng/ml, OGTT (2 h after 75 mg oral glucose): 5.7 ng/ml (normal value <1 ng/ml), TSH: 1.8 mIU/ml (0.27–4.2 mIU/ml): and free T4: 1.1 ng/dl (0.7–1.9 ng/dl). Now, the patient's general condition is favorable.
A 40-year-old male was referred to the endocrinology clinic in August 2006. The patient complained of weight gain, low libido, low sexual desire, and excessive sweating. Physical examination was notable for frontal bossing, macrognathia, coarse facial features, large hand, and feet. The thyroid examination and visual field test results were normal.
Laboratory values were notable for HbA1c: 6% (4%–6.5%), FBS: 124 mg/dl, IGF-1: 951 ng/dl (140–405 ng/dl), basal GH: 8.2 ng/ml (normal values were <1 ng/ml), GTT (1 h): 5.6 ng/ml, GTT (2 h): 4.7 ng/ml, FSH: 3.2 mIU/ml (4.7–21.5 mIU/ml), LH: 1 IU/L (0.5–16.9 IU/L), prolactin: 8 ng/ml (4–23 ng/ml), adrenocorticotropic hormone (ACTH): 15.1 pg/ml at 8 am (7.1–63 pg/ml), cortisol: 11 μg/dL at 8 am (10–20 μg/dL), testosterone: 0.6 ng/ml (2–6.9 ng/ml), TSH: 0.5 mIU/ml (0.27–4.2 mIU/ml), and free T4 of 0.7 ng/dl (0.7–1.9 ng/dl). Brain MRI was performed and revealed a macroadenoma in the pituitary gland. Transsphenoidal surgery was performed in September 2006. After surgery, the patient's symptoms relieved, but the disease was not controlled biochemically. Three months later, laboratory values were notable for IGF-1: 683 ng/dl (87–220 ng/dl), basal GH: 5.2 ng/ml, GTT (1 h); 4.3 ng/ml, GTT (2 h): 3.5 ng/ml, FSH: 2 mIU/ml (4.7–21.5 mIU/ml), LH: 0.9 IU/L (0.5–16.9 IU/L), testosterone: 0.5 ng/ml (2–6.9 ng/ml), prolactin: 7.8 ng/ml (4–23 ng/ml), ACTH: 10.2 pg/ml at 8 am (7.1–63 pg/ml), cortisol: 5 μg/dL at 8 am (10-20 μg/dL), TSH: 0.4 mIU/ml (0.27–4.2 mIU/ml), and free T4 of 5.7 ng/dl (0.7–1.9 ng/dl). Therefore, Sandostatin LAR (start at a dose of 20 mg, every 4 weeks and then uptitrated to a maximum dose of 30 mg, every 4 weeks) was administered. Prednisolone (5 mg/day), testosterone enanthate (200 mg every 3 weeks), and levothyroxine (100 μg daily) were also prescribed. In late 2015, the patient presented to our department with neck swelling. A thyroid nodule was detected during the physical examination, and PTC was detected by FNA biopsy. Therefore, the patient was scheduled for a total thyroidectomy. In macroscopic evaluation of lesion, maximum nodule diameter was 37 mm, and in microscopic evaluation, PTC without any extrathyroidal invasion was confirmed. Postoperatively, the patient received 100 mCi radioactive iodine, and then, he received on 0.15 mg thyroxine once a day. Now, the patient's general condition is favorable, and the last laboratory data reveal a GH of 1.6 ng/ml, IGF-1: 215 ng/dl (87–220 ng/dl), thyroglobulin (on-levothyroxine): 0.2 ng/ml, and negative antithyroglobulin antibody. Now, he is receiving Sandostatin LAR (30 mg every 4 weeks).
| Discussion|| |
In acromegalic patients, thyroid disturbance occurs as a thyroid dysfunction as well as benign or malignant structural disease. Several studies indicated that a chronic excess IGF-1 stimulates the proliferation of various cell types and induces an antiapoptotic effect in thyroid follicular cells., Some studies have suggested the potential role of pituitary irradiation, obesity, insulin, insulin resistance, leptin, IGF-binding proteins (BP) 1, and IGF-BP3 in inducing thyroid cancers., It is important to keep in mind that genetic susceptibility to pituitary tumors with overproduction of GH can also increase the risk of other tumors such as thyroid cancer due to epigenetic mechanisms. Thyroid cancer was reported as the most common cancer type in these patients.,, We describe three patients with acromegaly and papillary thyroid cancer. None had previous radiotherapy or family history of thyroid malignancy. In all the patients, the thyroid cancer was the papillary type. In two patients, acromegaly and PTC were simultaneously diagnosed, and in the third case, the PTC was diagnosed when the acromegaly was not controlled biochemically. Therefore, in all the patients, PTC was diagnosed in the presence of elevated IGF-1 levels. Recently, Tirosh and Shimon et al. summarized the main studies reporting rates of thyroid cancer among patients with acromegaly. They deduced that patients with acromegaly had higher rates of thyroid cancer compared with controls (3.2% vs. 0.3%). A meta-analysis of case–control studies showed an increased risk of thyroid cancer in acromegaly. In addition, the rate of thyroid cancer varied from 1.2% to 10.6% in different studies. Of course, some of the studies enrolled patients with small thyroid nodules for cytology evaluation. Therefore, this contributes to the diagnosis of thyroid microcarcinomas which are known as very low-risk tumors., Indeed, in some studies, the prevalence of thyroid cancer was reported only slightly higher than the general population., Furthermore, we need to take into consideration that prolonged and close follow-up of the acromegalic patients in endocrinology clinics can lead to overdiagnosis of thyroid cancers. In some studies, there was no relationship between age, sex, disease duration or IGF-1 levels, and cancer developments,,, but others reported gender-related differences. Higuchi et al. reported that male acromegalic patients might have a higher risk for thyroid malignancy. In general, although most patients with acromegaly were visited regularly by an endocrinologist and the thyroid cancer is often considered as a less aggressive tumor, routine thyroid examination may be necessary.
| Conclusion|| |
In the series of patients reported here, the size of papillary thyroid cancers was >1 cm and extrathyroidal extension was observed. It seems that extra attention should be paid on thyroid examinations in patients with acromegaly so that these thyroid complications should be discovered in earlier stages.
Declaration of patient consent
The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Ritvonen E, Löyttyniemi E, Jaatinen P, Ebeling T, Moilanen L, Nuutila P, et al
. Mortality in acromegaly: A 20-year follow-up study. Endocr Relat Cancer 2016;23:469-80.
Kaldrymidis D, Papadakis G, Tsakonas G, Kaldrymidis P, Flaskas T, Seretis A, et al.
High incidence of thyroid cancer among patients with acromegaly. J BUON 2016;21:989-93.
Siegel G, Tomer Y. Is there an association between acromegaly and thyroid carcinoma? A critical review of the literature. Endocr Res 2005;31:51-8.
Kurimoto M, Fukuda I, Hizuka N, Takano K. The prevalence of benign and malignant tumors in patients with acromegaly at a single institute. Endocr J 2008;55:67-71.
Terzolo M, Reimondo G, Berchialla P, Ferrante E, Malchiodi E, De Marinis L, et al.
Acromegaly is associated with increased cancer risk: A survey in Italy. Endocr Relat Cancer 2017;24:495-504.
Baris D, Gridley G, Ron E, Weiderpass E, Mellemkjaer L, Ekbom A, et al.
Acromegaly and cancer risk: A cohort study in Sweden and Denmark. Cancer Causes Control 2002;13:395-400.
Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, et al.
Diabetes and cancer: A consensus report. CA Cancer J Clin 2010;60:207-21.
Erdogan-Durmus S, Ozcan D, Yarikkaya E, Kurt A, Arslan A. CD56, HBME-1 and cytokeratin 19 expressions in papillary thyroid carcinoma and nodular thyroid lesions. J Res Med Sci 2016;21:49. [Full text]
Higuchi Y, Saeki N, Iuchi T, Uchino Y, Tatsuno I, Uchida D, et al.
Incidence of malignant tumors in patients with acromegaly. Endocr J 2000;47 Suppl: S57-60.
Tirosh A, Shimon I. Complications of acromegaly: Thyroid and colon. Pituitary 2017;20:70-5.
Wolinski K, Czarnywojtek A, Ruchala M. Risk of thyroid nodular disease and thyroid cancer in patients with acromegaly – Meta-analysis and systematic review. PLoS One 2014;9:e88787.
Dagdelen S, Cinar N, Erbas T. Increased thyroid cancer risk in acromegaly. Pituitary 2014;17:299-306.
Dąbrowska AM, Tarach JS, Kurowska M, Nowakowski A. Thyroid diseases in patients with acromegaly. Arch Med Sci 2014;10:837-45.
Gullu BE, Celik O, Gazioglu N, Kadioglu P. Thyroid cancer is the most common cancer associated with acromegaly. Pituitary 2010;13:242-8.